Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	557.28	444.09	281.59	202.13	402.71	129.09
Depreciation & Amortization	81.73	81.31	82.36	49.64	3	3.28
Other Amortization	7.38	7.35	7.3	7.84	3.64	14.14
Loss (Gain) From Sale of Assets	-0.15	1.53	0.61	0.13	-	-0.77
Asset Writedown & Restructuring Costs	-	-	2.5	-	-	0.58
Loss (Gain) From Sale of Investments	-8.34	-10.93	-6.32	2.83	2.26	0.84
Stock-Based Compensation	46.87	43.39	36.62	24.4	20.82	17.2
Other Operating Activities	-23.88	1.6	22.58	39.09	-136.72	-0.53
Change in Accounts Receivable	-101.82	-74.25	-3.34	-83.94	6.76	-38.29
Change in Inventory	-20.87	-67.38	-26.88	-17.48	7.37	-31.39
Change in Accounts Payable	6.53	46.99	-12.55	24.54	1.17	-41.21
Change in Other Net Operating Assets	3.04	5.36	4.1	-9.06	-11.56	2.52
Operating Cash Flow	547.78	479.06	388.57	240.11	299.44	55.45
Operating Cash Flow Growth	30.43%	23.29%	61.83%	-19.81%	439.98%	-
Capital Expenditures	-7.08	-10.7	-15.29	-4.81	-1.46	-2.5
Sale of Property, Plant & Equipment	-	-	-	26.01	-	1.08
Cash Acquisitions	-	-	-	-999.12	-	-
Investment in Securities	-136.56	-252.03	-81.62	490.92	-404.83	79.78
Investing Cash Flow	-143.64	-262.72	-96.91	-487.01	-406.29	78.35
Short-Term Debt Issued	-	-	-	370	-	-
Long-Term Debt Issued	-	-	-	702	784.88	-
Total Debt Issued	-	-	-	1,072	784.88	-
Short-Term Debt Repaid	-	-	-	-370	-	-
Long-Term Debt Repaid	-	-	-13.48	-77.45	-369.06	-19.56
Total Debt Repaid	-	-	-13.48	-447.45	-369.06	-19.56
Net Debt Issued (Repaid)	-	-	-13.48	624.55	415.81	-19.56
Issuance of Common Stock	23.35	31.14	7.88	14.05	12.54	63.39
Repurchase of Common Stock	-553.49	-250	-402.38	-200	-350.06	-150.12
Other Financing Activities	-	-	-	-76.22	-0.42	-
Financing Cash Flow	-530.14	-218.86	-407.99	362.37	77.87	-106.28
Net Cash Flow	-126	-2.52	-116.33	115.48	-28.98	27.52
Free Cash Flow	540.69	468.37	373.28	235.3	297.98	52.95
Free Cash Flow Growth	32.42%	25.47%	58.64%	-21.04%	462.76%	-
Free Cash Flow Margin	45.87%	46.13%	45.01%	35.64%	67.22%	19.79%
Free Cash Flow Per Share	4.24	3.62	2.78	1.67	2.03	0.37
Cash Interest Paid	10.57	10.57	11.41	6.11	3.3	6.53
Cash Income Tax Paid	80.62	80.62	31.76	16.22	-0.38	0.18
Levered Free Cash Flow	429.68	395.43	274.74	146.42	197.82	3.92
Unlevered Free Cash Flow	433.54	399.38	279.16	149.17	198.88	2.52
Change in Working Capital	-113.12	-89.28	-38.67	-85.95	3.74	-108.37

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q